Pluristem Therapeutics Inc.
PSTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.02 | -0.03 | 0.00 |
| FCF Yield | -6.16% | 27.03% | -7.43% | 8.05% |
| EV / EBITDA | -16.01 | -6.11 | -12.85 | -2.12 |
| Quality | ||||
| ROIC | 43.30% | 18.25% | 109.52% | 135.29% |
| Gross Margin | 36.39% | 35.31% | 31.85% | 60.00% |
| Cash Conversion Ratio | 0.89 | 2.08 | 0.66 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,123,362.92% | 1,101,275.69% | 232.57% | 163.12% |
| Free Cash Flow Growth | -132.36% | 451.02% | -1,191.72% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.42 | -0.08 | -1.12 | -1.06 |
| Interest Coverage | -27.86 | 1.97 | -26.38 | -24.65 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -589.25 | -377.32 | -385.05 | -1,348.78 |